Remove

Under the Paperwork Reduction Act of 1995, no persons are required to resp

	Application Number		10519419	
	Filing Date		2004-12-22	
	First Named Inventor	Valer	rij Tatarsky	
	Art Unit		1614	
	Examiner Name	TBA		
	Attorney Docket Number		101215-170	

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	,	Name of Pate of cited Docu	Releva	,Columns,l ant Passag s Appear			
	1	6110529	A	2000-08-29	•	Vaartstra Bna	n A et al.	Entire	document		
	2	5225561	A	1993-07-06	5	Brown Duncar	n W.etal.	Entire	document		
	3	4814391	A	1989-03-21	ı	Colborn Robe	đE.	Entire	document		
If you wis	h to a	d additional U.S. Pater	t citatio	n informatio	n pl	ease click the	Add button.		Add		
			U.S.P	ATENT AP	PLI	CATION PUBL	LICATIONS		Remove		
		Publication Publication Name of Patentee or Applicant of cited Document		Releva	,Columns,l ant Passag s Appear						
	1							Entire	document		
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication cit	ation	information p	lease click the Ad	d buttor	n. Add		
				FOREIGN	PAT	ENT DOCUM	ENTS		Remove		
Examiner Cite Initial* No		Foreign Document Number ³	Country Code ²			Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Colu where Rele Passages of Figures Ap	vant or Relevant	т
Initial*	No							- 1			

U.S.PATENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10519419
Filing Date		2004-12-22
First Named Inventor Valer		nj Tatarsky
Art Unit		1614
Examiner Name TBA		
Attorney Docket Numb	er	101215-170

			Attorr	Attorney Docket Number 101215-170					
						_			
	2	90 06749	wo		1990-06-28	c	IKY Gulden Lomberg themische Fabrik ambH	Entire document. Cited in ISR - document not provided	
If you wis	h to a	dd additional Foreign P	stent Document	citation	information pl	ea	se click the Add buttor	Add	_
			NON-PATE	NT LITE	RATURE DO	CL	IMENTS	Remove	
Examiner Initials*	Cite No	Include name of the ai (book, magazine, journ publisher, city and/or of	nal, serial, symp	osium,	catalog, etc), o				T6
	1	Tembe G. L. et al.; "Manganese (II) beth-dikebnate catalysed oxidation of cyclohexane by tert-bufy hydroperoxide"; Reaction Kinetoc and Catalysis Letters. Elsevier, Ansterdam, NL, Volume G3, Number 2, 1998, pages 395-399.							
	2	Naturagn C. et al. "Synthesis, spectral studies and reactivity of rollsel (II), copper (II) and zinc (II) mixed (igand complexes with "Jórmy," 2-acepting and 2-benzoly-colpitationners and laceblostene" Synthesis and Reactivity in Inorganic and Metallorganic Chemistry, Marcel Deliker Incorporated, New York, US, Volume 22, Number 6, 1992, pages 827-846. CTED NI ISP: COPP OF DOCUMENT NOT PROVIDED.							
	3	Bennett, Alison M. A. et al.: The IR and proton, carbon-10 NMR spectra of the nickel (II), copper (II) and zno (II) complexes of 2.4 pentancent, e-thioso-2 pentancen are 1.5 pentancen, e-thioso-2 pentancen, e-t							
	4	Such K. P. et al.; "E.P.R. of Mn(2+) in adelylacetonaties", Molecular Physics, London, GB, Volume 60, Number 3, 1997, pages 553-560. CITED IN ISR - COPY OF DOCUMENT NOT PROVIDED.							
	5	Kirsie, Burkharr et al.: "ENDOR study of bis(acetylacetonato) copper (II) in solid solution", Journal of Physical Chemistry, American Chemical Society, US, Volume 97, Number 5, March 3, 1983, pages 781-788. CITED IN ISR -							
	6	Database CA Online! Chemical Abstracts Service, Columbus Onlo, US, Boguslavskii, E. G. et al.: "ESR study of copper (II) complexes with substituted thoursess", retrieved from STN, Database accession no. 94 40629. CITED IN							
	7	for the iron/copper binud	lear active site of Volume 102, Num	cytochro	ome oxidase"; Jo	our		exes as synthetic models mical Society, American I ISR - COPY OF	
	8						II) chelates with organic r 10, 1978, pages 1495-	bases*, Russian Journal 1501. CITED IN ISR -	П

COPY OF DOCUMENT NOT PROVIDED.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10519419
Filing Date		2004-12-22
First Named Inventor Valer		ıj Tatarsky
Art Unit		1614
Examiner Name TBA		
Attorney Docket Numb	er	101215-170

Date Considered

	9	Haider, S. Z. et al.; Copper complexes of the derivatives of 2.4 pentamedione*, Journal of the Bangladesh Academy of Sciences, Volume 1, Number 2, 1977, pages 53-62. CITED IN ISR - COPY OF DOCUMENT NOT PROVIDED.	
	10	Kwiatkowski, Edmund, "Calculation of formation constants for 1:1 complexes from spectrophotometric data", Journal of Inorganic and Nuclear Chemistry, Pergamon Press Limited, Oxford, GB, Volume 39, Number 9, 1977, pages 1611-1613. CITED IN ISR - COPY OF DOCUMENT NOT PROVIDED.	
	11	Locznaka, Airiga et al., "X-ray and humnescence spectral investigation of chelates of zinc (II) and some other transition metals with beta-disobrate of the R-CC-CR2-CO-R1 type". Rocznaki Okennii, Amates Societas Chemica	
	12	Tamura, Hirosh et al.; "DNA binding and cleaving activity of artiflumor metal complex: socilum trans-dintrobis(2,4-pertanetionato):obat (III); "Chemistry Letters, Chemical Society of Japan, Totyo, JP, Number 8, 1997, pages 711-712. CTED in INSR-CCPV OF DOCUMENT NOT PROVIDED.	
If you wi	sh to a	dd additional non-patent literature document citation information please click the Add button Add	
		EYAMINED SIGNATURE	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USFTO Plantin Documents at year, USFTO, 000/c or MEPP 910.6. * Enter office and issued for document, by the to-electr code (WIPO Standard ST3.). **Explainate petatio Comments, the redication for legar of the region of the Engerer many reported the senior instruct for paperto forward. **If the Engerer many reported the senior instruct for the patent document. **If Add of Comment by the appropriate symptom as indicated on the document under WIPO Standard ST.16 if possible. **Applicant is to place a check mark here if training instructions attached.**

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10519419		
Fifing Date First Named Inventor Valen Art Unit Examiner Name TBA Attorney Docket Number		2004-12-22		
		ıj Tatarsky		
		1614		
		101215-170		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.9	8 to make the	e appropri	ate selection(s	à:
---------------	----------	---------	---------------	------------	-----------------	----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information siclosure statement. See 37 CFR 197(e)(1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/bruce s londa/	Date (YYYY-MM-DD)	2006-07-24
Name/Print	Bruce S. Londa	Registration Number	33531

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GA 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandriu, V.S. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.